Compagnie Lombard Odier SCmA’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $73.9M | Sell |
395,004
-15,767
| -4% | -$2.97M | 0.8% | 27 |
|
|
2026
Q1 | $79.6M | Buy |
+410,771
| New | +$79.2M | 0.98% | 26 |
|
|
2025
Q2 | – | Sell |
-1,190
| Closed | -$175K | – | 449 |
|
|
2025
Q1 | $175K | Buy |
+1,190
| New | +$172K | ﹤0.01% | 263 |
|
|
2024
Q1 | – | Sell |
-200
| Closed | -$26.9K | – | 495 |
|
|
2023
Q4 | $26.9K | Buy |
+200
| New | +$26K | ﹤0.01% | 449 |
|
|
2022
Q2 | – | Sell |
-250
| Closed | -$33K | – | 604 |
|
|
2022
Q1 | $33K | Hold |
250
| – | – | ﹤0.01% | 486 |
|
|
2021
Q4 | $29K | Hold |
250
| – | – | ﹤0.01% | 552 |
|
|
2021
Q3 | $30K | Sell |
250
-150
| -38% | -$17.5K | ﹤0.01% | 536 |
|
|
2021
Q2 | $48K | Hold |
400
| – | – | ﹤0.01% | 494 |
|
|
2021
Q1 | $40K | Buy |
+400
| New | +$40.2K | ﹤0.01% | 532 |
|
|
2018
Q4 | – | Sell |
-70
| Closed | -$6K | – | 555 |
|
|
2018
Q3 | $6K | Hold |
70
| – | – | ﹤0.01% | 529 |
|
|
2018
Q2 | $5K | Hold |
70
| – | – | ﹤0.01% | 570 |
|
|
2018
Q1 | $5K | Sell |
70
-243
| -78% | -$16.8K | ﹤0.01% | 576 |
|
|
2017
Q4 | $22K | Buy |
313
+243
| +347% | +$16.4K | ﹤0.01% | 576 |
|
|
2017
Q3 | $5K | Hold |
70
| – | – | ﹤0.01% | 659 |
|
|
2017
Q2 | $5K | Hold |
70
| – | – | ﹤0.01% | 672 |
|
|
2017
Q1 | $4K | Sell |
70
-1,000
| -93% | -$58.2K | ﹤0.01% | 695 |
|
|
2016
Q4 | $59K | Sell |
1,070
-2,000
| -65% | -$114K | ﹤0.01% | 588 |
|
|
2016
Q3 | $202K | Hold |
3,070
| – | – | 0.01% | 475 |
|
|
2016
Q2 | $185K | Hold |
3,070
| – | – | 0.01% | 485 |
|
|
2016
Q1 | $173K | Buy |
3,070
+1,000
| +48% | +$60.1K | 0.01% | 515 |
|
|
2015
Q4 | $141K | Buy |
2,070
+670
| +48% | +$43.9K | ﹤0.01% | 538 |
|
|
2015
Q3 | $89K | Hold |
1,400
| – | – | ﹤0.01% | 537 |
|
|
2015
Q2 | $89K | Hold |
1,400
| – | – | ﹤0.01% | 574 |
|
|
2015
Q1 | $96K | Buy |
1,400
+1,300
| +1,300% | +$90.3K | ﹤0.01% | 669 |
|
|
2014
Q4 | $7K | Hold |
100
| – | – | ﹤0.01% | 728 |
|
|
2014
Q3 | $7K | Hold |
100
| – | – | ﹤0.01% | 834 |
|
|
2014
Q2 | $7K | Hold |
100
| – | – | ﹤0.01% | 849 |
|
|
2014
Q1 | $6K | Hold |
100
| – | – | ﹤0.01% | 839 |
|
|
2013
Q4 | $6K | Buy |
+100
| New | +$5.43K | ﹤0.01% | 827 |
|
Other funds holding AZN
EP
IA
Compagnie Lombard Odier SCmA's AZN Position: Q2 2026 in Review
Compagnie Lombard Odier SCmA reduced its AstraZeneca (AZN) stake by 3.8% in Q2 2026, selling an estimated $2.97M and leaving 395,004 shares worth $73.9M. The position accounts for 0.8% of the portfolio, ranked #27.
Compagnie Lombard Odier SCmA first reported a position in AZN in Q4 2013 and has held it in 29 quarters since. The position peaked at $79.6M in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Compagnie Lombard Odier SCmA held 395,004 shares of AstraZeneca worth $73.9M as of Q2 2026.
- Compagnie Lombard Odier SCmA sold 15,767 AstraZeneca shares in Q2 2026, an estimated $2.97M.
- AstraZeneca made up 0.8% of Compagnie Lombard Odier SCmA's portfolio in Q2 2026, its #27 holding.
- Compagnie Lombard Odier SCmA first reported a position in AstraZeneca in Q4 2013 and has held it in 29 quarters since.
- Compagnie Lombard Odier SCmA's AstraZeneca position peaked at $79.6M in Q1 2026.
- 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Compagnie Lombard Odier SCmA's 13F filing for Q2 2026, filed 29 Jul 2026.